AngioDynamics Inc. Q1 Loss Decreases, Beats Estimates

AngioDynamics Inc. (ANGO) reported a first-quarter adjusted loss of -$0.10 per share, outperforming analyst expectations of -$0.12 per share, on revenue that grew 12.2% year-over-year to $75.711 million. The company also raised its fiscal 2026 revenue outlook to $308 million-$313 million and increased its adjusted EBITDA guidance to $6 million-$10 million, signaling improved profitability expectations. This positive news led to a 5.60% increase in ANGO's pre-market trading.

Analysis

AngioDynamics Inc. (ANGO) reported a strong first quarter, exceeding analyst expectations and raising its forward-looking guidance. The company posted an adjusted loss of -$0.10 per share, which was narrower than the consensus estimate of a -$0.12 loss, alongside a significant 12.2% year-over-year revenue increase to $75.711 million. This performance indicates solid top-line momentum and better-than-anticipated cost management. More importantly, management revised its fiscal 2026 outlook upwards, projecting revenue of $308 million to $313 million, which is above both its prior guidance and the analyst consensus of $307.2 million. The profitability forecast was also notably improved, with the adjusted EBITDA guidance raised to a range of $6 million to $10 million from a prior $3 million to $8 million. This combination of a current-quarter beat and a material raise in full-year guidance for both revenue and profitability signaled strong underlying business health, prompting a 5.60% increase in the stock's pre-market trading session.

Key Decisions for Investors

• The strong earnings beat and upwardly revised guidance for both revenue and adjusted EBITDA provide a bullish signal, suggesting investors may consider initiating or adding to positions as the company demonstrates a clear path toward improved profitability.
• Investors should monitor the company's ability to execute on its new guidance, paying close attention to quarterly progress toward the raised adjusted EBITDA target of $6 million to $10 million, as this is a key indicator of margin improvement.
• Given the 5.60% pre-market stock appreciation, it is prudent to assess if the market has fully priced in the positive news or if the new growth and profitability trajectory justifies a further re-rating relative to peers.